ValuEngine upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a report issued on Friday.
A number of other analysts also recently issued reports on the stock. BidaskClub raised shares of TG Therapeutics from a sell rating to a hold rating in a report on Tuesday. B. Riley reissued a buy rating and set a $21.50 price target on shares of TG Therapeutics in a report on Wednesday, January 17th. HC Wainwright reissued a buy rating and set a $33.00 price target on shares of TG Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research downgraded shares of TG Therapeutics from a hold rating to a sell rating in a report on Saturday, January 13th. Finally, Raymond James Financial reissued a buy rating on shares of TG Therapeutics in a report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. TG Therapeutics currently has a consensus rating of Buy and a consensus price target of $25.50.
Shares of TG Therapeutics (NASDAQ TGTX) traded up $0.50 during midday trading on Friday, reaching $11.80. 2,618,958 shares of the company were exchanged, compared to its average volume of 1,420,000. TG Therapeutics has a 12-month low of $4.50 and a 12-month high of $15.35. The stock has a market capitalization of $870.59, a P/E ratio of -6.11 and a beta of 1.67.
In other TG Therapeutics news, CFO Sean A. Power sold 32,006 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 16.70% of the company’s stock.
Large investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in TG Therapeutics by 14.9% during the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 1,463 shares during the period. Voya Investment Management LLC raised its position in TG Therapeutics by 40.2% during the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 6,463 shares during the period. Nationwide Fund Advisors raised its position in TG Therapeutics by 24.2% during the second quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 5,167 shares during the period. CIBC World Markets Inc. acquired a new position in TG Therapeutics during the fourth quarter worth $250,000. Finally, The Manufacturers Life Insurance Company raised its position in TG Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 36,754 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 7,630 shares during the period. Institutional investors own 50.43% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.